Search Result
Results for "
tolerance
" in MedChemExpress (MCE) Product Catalog:
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N8522
-
|
|
Others
|
Metabolic Disease
|
|
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice .
|
-
-
- HY-W015399
-
|
|
Fungal
|
Infection
|
|
4-Methylcinnamic acid, a Cinnamic acid analog, can be used as a intervention catalyst for overcoming antifungal tolerance. 4-Methylcinnamic acid can improve the potency of cell wall-disrupting agents .
|
-
-
- HY-126478
-
|
|
Proton Pump
|
Others
|
|
Quinabactin is a sulfonamide Abscisic acid (ABA) agonist. Quinabactin promotes guard cell closure, inhibits water loss, and promotes drought tolerance in adult Arabidopsis and soybean plants .
|
-
-
- HY-P1290A
-
|
PKI-(6-22)-amide TFA
|
PKA
|
Neurological Disease
|
|
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
|
-
-
- HY-162467
-
|
|
Proton Pump
|
Others
|
|
Opabactin is an agonist for abscisic acid (ABA) receptor, which regulates the water use of plants by mimicking the effects of ABA with an IC50 of 7 nM. Opabactin inhibits the seed germination of Arabidopsis with an IC50 of 62 nM. Opabactin induces anti-transpiration response in plant tissue, and improves crop drought tolerance .
|
-
-
- HY-P1290
-
|
PKI-(6-22)-amide
|
PKA
|
Neurological Disease
|
|
PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .
|
-
-
- HY-101247
-
|
|
mGluR
|
Neurological Disease
|
|
MTPG is a potent mGluR2 and mGluR3 antagonist. MTPG can block the induction of brain ischemic tolerance induced by cerebral ischemic preconditioning. MTPG also significantly attenuates the inhibitory effect of L-CCG-1 on the KCl-evoked dopamine release .
|
-
-
- HY-17538A
-
|
|
PGC-1α
|
Metabolic Disease
|
|
ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity .
|
-
-
- HY-N12353
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC50: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .
|
-
-
- HY-161281
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC50 of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .
|
-
-
- HY-123297
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .
|
-
-
- HY-N9410
-
|
1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .
|
-
-
- HY-151425
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC50 value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo .
|
-
-
- HY-N7515
-
|
2',4',6'-Trihydroxychalcone
|
Bacterial
AMPK
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .
|
-
-
- HY-149274
-
|
|
Sigma Receptor
|
Neurological Disease
|
|
Sigma-1 receptor antagonist 4 (Compound 32) is a potent σ1R antagonist that significantly enhances the analgesic effect of morphine and rescues morphine-induced analgesic tolerance, with potential to prevent morphine tolerance .
|
-
-
- HY-162174
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit New Delhi Metallo-β-lactamase-1 (NDM-1) with an IC50 of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics .
|
-
-
- HY-126774
-
|
|
Fluorescent Dye
|
Others
|
|
DAF-FM is a diaminofluorescein, which can be used as fluorescent indicator for nitric oxide (NO) with good pH tolerance .
|
-
-
- HY-A0235
-
|
Stakane
|
Others
|
Neurological Disease
|
|
Antrafenine (Stakane) is a non-narcotic analgesic, shows long duration of action, and excellent tolerance in pharmacological and toxicological studies .
|
-
-
- HY-170874
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for PPARγ that inhibits PPARγ ligand-binding domain (LBD) with an IC50 of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models .
|
-
-
- HY-153182
-
-
-
- HY-117830
-
|
|
Phosphatase
|
Endocrinology
|
|
CX08005 is a competitive PTP1B inhibitor. CX08005 can directly enhance the action of insulin in vivo and in vitro and improve insulin resistance .
|
-
-
- HY-150012
-
-
-
- HY-128578
-
|
|
PDHK
|
Metabolic Disease
Inflammation/Immunology
|
|
KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice .
|
-
-
- HY-164781
-
-
-
- HY-125025
-
-
-
- HY-12853
-
|
|
Reactive Oxygen Species (ROS)
|
Others
|
|
Mesotrione is a herbicide belongs to the benzoylcyclohexanedione family. Mesotrione is a potent and competitive and reversible inhibitor of HPPD enzyme. Mesotrione is selective to maize due to rapid metabolism and relative high tolerance by the susceptible crop plant .
|
-
-
- HY-136376
-
|
|
Herbicide
Glutathione S-transferase
|
Others
|
|
Mefenpyr-diethyl is an herbicide safener. Mefenpyr-diethyl enhances plant tolerance to herbicides by inducing the expression of antioxidant enzymes such as GST. Mefenpyr-diethyl protects crops against herbicide injury .
|
-
-
- HY-112330
-
|
|
PKA
|
Neurological Disease
|
|
4-Cyano-3-methylisoquinoline is an inhibitor for protein kinase A (PKA) with an IC50 of micromolar level. 4-Cyano-3-methylisoquinoline reverses morphine tolerance in mouse model .
|
-
-
- HY-114492
-
|
GSK'547
|
RIP kinase
|
Cancer
|
|
GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer .
|
-
-
- HY-170909
-
|
|
PIKfyve
|
Others
|
|
PIKfyve-IN-4 (Compound 40) is an orally active and selective inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), with an IC50 of 0.60 nM. PIKfyve-IN-4 exhibits good systemic tolerance .
|
-
-
- HY-108402
-
|
|
Penicillin-binding protein (PBP)
Bacterial
Antibiotic
|
Infection
|
|
Cefodizime is a third generation cephalosporin antibiotic with a broad spectrum of antibacterial activity. Cefodizime has no renal toxic effect, good tolerance and immune regulation activity, and has the potential for severe infections of the respiratory and urinary tracts .
|
-
-
- HY-N0630
-
|
|
GCGR
|
Neurological Disease
|
|
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .
|
-
-
- HY-108402A
-
|
|
Penicillin-binding protein (PBP)
Bacterial
Antibiotic
|
Infection
|
|
Cefodizime sodium is a third generation cephalosporin antibiotic with a broad spectrum of antibacterial activity. Cefodizime sodium has no renal toxic effect, good tolerance and immune regulation activity, and can be used for the research of severe infections of the respiratory and urinary tracts .
|
-
-
- HY-N13250
-
|
|
Others
|
Cardiovascular Disease
|
|
Hawthorn Extract is a hawthorn extract, and its components include: Vitexin-2-O-rhamnoside. Hawthorn Extract is an orally active, anti-chronic heart failure protector that can improve exercise tolerance and reduce heart rate. .
|
-
-
- HY-N2486
-
|
|
Fatty Acid Synthase (FASN)
Apoptosis
|
Cancer
|
|
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
|
-
-
- HY-129451
-
|
|
GABA Receptor
|
Others
|
|
HIE-124 is a potent ultra-short acting hypnotic that exhibits a rapid onset of action and a shorter duration of action with no acute tolerance or noticeable side effects. HIE-124 is promising for research of preanesthetic medication and anesthesia inducer .
|
-
-
- HY-114492A
-
|
|
RIP kinase
|
Cancer
|
|
(Rac)-GSK547 is the racemate of GSK547. GSK547 is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIP1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer .
|
-
-
- HY-104006
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC50 of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .
|
-
-
- HY-113478
-
|
Isoursodeoxycholic acid
|
Drug Metabolite
|
Metabolic Disease
|
|
3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .
|
-
-
- HY-129736A
-
|
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
P32/98 a potent inhibitor of dipeptidyl peptidase IV with a Ki value of 130 nM. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .
|
-
-
- HY-P1291
-
|
|
PKA
Epigenetic Reader Domain
Flavivirus
|
Infection
Neurological Disease
|
|
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
|
-
-
- HY-N13082
-
|
|
Others
|
Metabolic Disease
|
|
Deacetylescin Ia (compound 12) is a deacetylated compound with anti-hyperglycemic effects that can be extracted from the debittered Aesculus and deacetylated at the C-22 position. Deacetylescin Ia (100 mg/kg) can inhibit blood glucose elevation in mouse glucose tolerance tests .
|
-
-
- HY-129736
-
|
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a Ki value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .
|
-
-
- HY-P1291A
-
|
|
PKA
Epigenetic Reader Domain
Flavivirus
|
Infection
Neurological Disease
|
|
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
|
-
-
- HY-139289S
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
ART899 is a highly specific allosteric inhibitor of the Polθ DNA polymerase domain. ART899 can effectively enhance the radiosensitivity of tumor cells, shows good tolerance when combined with fractionated radiation, and significantly reduces tumor growth compared to radiation alone .
|
-
-
- HY-150012R
-
|
|
Endogenous Metabolite
|
Metabolic Disease
Endocrinology
|
|
N-Lactoyl-Phenylalanine (Standard) is the analytical standard of N-Lactoyl-Phenylalanine. This product is intended for research and analytical applications. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .
|
-
-
- HY-124680
-
|
AC-093
|
Neuropeptide FF Receptor
|
Inflammation/Immunology
|
AC-263093 free base (AC-093) functionally activates NPFFR2 and blocks activation of NPFFR1 with pKis of 6.9 and 7.0, respectively. AC-263093 free base has the potential for reversing opiate tolerance research .
.
|
-
-
- HY-12853R
-
|
|
Reference Standards
Reactive Oxygen Species (ROS)
|
Others
|
|
Mesotrione (Standard) is the analytical standard of Mesotrione. This product is intended for research and analytical applications. Mesotrione is a herbicide belongs to the benzoylcyclohexanedione family. Mesotrione is a potent and competitive and reversible inhibitor of HPPD enzyme. Mesotrione is selective to maize due to rapid metabolism and relative high tolerance by the susceptible crop plant .
|
-
-
- HY-138885
-
|
TpGc
|
Tyrosinase
DNA/RNA Synthesis
|
Neurological Disease
|
|
Tryptamine guanosine carbamate (TpGc) is a selective HINT1 (histidine triad nucleotide-binding protein 1) inhibitor (Ki=34 μM, Kd=3.65 μM). Tryptamine guanosine carbamate significantly enhances morphine antinociception while preventing the development of tolerance .
|
-
-
- HY-152259
-
|
|
TMV
|
Infection
|
|
TMV-IN-4 (compound 3) is a tobacco mosaic virus (TMV) inhibitor that effectively induces resistance and enhances plant tolerance to TMV infection by interacting with TMV helicase. TMV-IN-4 enhances peroxidase and superoxide dismutase activity, thereby increasing resistance to TMV in tobacco .
|
-
- HY-162893
-
|
|
Glycosidase
|
Metabolic Disease
|
|
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
|
-
- HY-144642
-
|
|
PARP
|
Cancer
|
|
PARP-1-IN-1 is a high selective and orally active PARP-1 inhibitor (IC50=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model .
|
-
- HY-136376R
-
|
|
Herbicide
Reference Standards
|
Others
|
|
Mefenpyr-diethyl (Standard) is the analytical standard of Mefenpyr-diethyl. This product is intended for research and analytical applications. Mefenpyr-diethyl is an herbicide safener. Mefenpyr-diethyl enhances plant tolerance to herbicides by inducing the expression of antioxidant enzymes such as GST. Mefenpyr-diethyl protects crops against herbicide injury .
|
-
- HY-108402R
-
|
|
Penicillin-binding protein (PBP)
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Cefodizime (Standard) is the analytical standard of Cefodizime. This product is intended for research and analytical applications. Cefodizime is a third generation cephalosporin antibiotic with a broad spectrum of antibacterial activity. Cefodizime has no renal toxic effect, good tolerance and immune regulation activity, and has the potential for severe infections of the respiratory and urinary tracts .
|
-
- HY-155553
-
|
|
GPR119
|
Metabolic Disease
|
|
GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes .
|
-
- HY-150012S1
-
-
- HY-170781
-
|
|
LIM Kinase (LIMK)
|
Metabolic Disease
|
|
MDI-114215 (compound 85) is an allosteric LIMK1/2 dual inhibitor with good in vivo tolerance. MDI-114215 can inhibit cofilin phosphorylation in mouse brain region-induced pluripotent stem cells (iPSCs), which can be used for Fragile X Syndrome (FXS) research .
|
-
- HY-B0853
-
|
|
Fungal
|
Infection
|
|
Paclobutrazol is a triazole-containing plant growth retardant that is known to inhibit the biosynthesis of gibberellins. Paclobutrazol also has antifungal activities. Paclobutrazol, transported acropetally in plants, can also suppress the synthesis of abscisic acid and induce chilling tolerance in plants. Paclobutrazol is typically used to support research on the role of gibberellins in plant biology .
|
-
- HY-B0999
-
|
Clorindanol; 7-Chloro-4-indanol
|
Bacterial
|
Infection
|
|
Chlorindanol (7-Chloro-4-indanol) is a topical antiseptic or sanitizer. Chlorindanol is rapidly lethal to vegetative bacteria, Trichophyton sp., C. albicans, E. histolytica cysts and trophozoites, T. vaginalis, and spermatozoa in vitro. Chlorindanol is klow systemic toxicity, well skin/eyes/genital mucosa tolerance and nonallergenic.
|
-
- HY-N0630R
-
|
|
Reference Standards
GCGR
|
Neurological Disease
|
|
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .
|
-
- HY-P1434
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .
|
-
![[Pro3]-GIP (mouse)](//file.medchemexpress.eu/product_pic/hy-p1434.gif)
- HY-108402AR
-
|
|
Penicillin-binding protein (PBP)
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Cefodizime (sodium) (Standard) is the analytical standard of Cefodizime (sodium). This product is intended for research and analytical applications. Cefodizime sodium is a third generation cephalosporin antibiotic with a broad spectrum of antibacterial activity. Cefodizime sodium has no renal toxic effect, good tolerance and immune regulation activity, and can be used for the research of severe infections of the respiratory and urinary tracts[1][2].
|
-
- HY-110197
-
6bK TFA
1 Publications Verification
|
Insulin Receptor
|
Metabolic Disease
|
|
6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice .
|
-
- HY-B2024
-
|
|
Herbicide
|
Others
|
|
Cloquintocet-mexyl is a herbicide safener. Cloquintocet-mexyl promotes the expression of genes related to chlorophyll synthesis (such as GTR and PPO) and chlorophyll-binding protein genes (CBP), increases the chlorophyll content, thereby promoting photosynthesis and reducing oxidative stress. Cloquintocet-mexyl improves wheat tolerance to Fomesafen (HY-B2010) .
|
-
- HY-W709961
-
|
1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .
|
-
- HY-146496
-
|
|
Bacterial
|
Infection
|
|
Antitubercular agent-20 (Compound 2d) is an orally active antitubercular agent. Antitubercular agent-20 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-20 has low cytotoxicity and good tolerance in BALB/c mice .
|
-
- HY-N2486R
-
|
|
Reference Standards
Fatty Acid Synthase (FASN)
Apoptosis
|
Cancer
|
|
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .
|
-
- HY-144289
-
|
|
Glucokinase
|
Metabolic Disease
|
|
BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .
|
-
- HY-160514
-
|
|
Phosphatase
|
Metabolic Disease
|
|
LXQ46 is an orally active inhibitor for protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 0.190 μM. LXQ46 enhances insulin and leptin signaling pathways in insulin-resistant C2C12. LXQ46 ameliorates type 2 diabetes and increases insulin tolerance in mouse models .
|
-
- HY-169411
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-77 (Compound H7) is a non-competitive inhibitor for α-glucosidase with an IC50 of 1.25 μM. α-Glucosidase-IN-77 lowers blood glucose levels, improves glucose tolerance, regulates intestinal microbiota, and exhibits hepatoprotective effect in mouse type 2 diabetes model .
|
-
- HY-133675
-
|
MECPP
|
Drug Metabolite
|
Others
|
|
Mono(5-carboxy-2-ethylpentyl) phthalate (MECPP) is a metabolite of Di-(2-ethylhexyl) phthalate (DEHP). Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
- HY-N0936
-
Coixol
1 Publications Verification
6-Methoxy-2-benzoxazolinone; 6-MBOA
|
Others
|
Inflammation/Immunology
|
|
Coixol (6-Methoxy-2-benzoxazolinone;6-MBOA) is a polyphenol extracted from coix (Coix lachryma-jobi L.var.ma-yuen Stapf) with antimicrobial and antitumor activities .
|
-
- HY-106072
-
|
LY 104208
|
Microtubule/Tubulin
|
Cancer
|
|
Vinzolidine is a semisynthetic derivative of the catharanthus alkaloid. Vinzolidine exerts its cytotoxic effect on tumor cells by interfering with microtubulin polymerization, thereby inhibiting cell division. Vinzolidine can be utilized in research to investigate synergistic effects when combined with other chemotherapeutic agents or biologic therapies, as well as to study cancer cells' tolerance or resistance to these treatments, and to explore approaches to overcome such obstacles .
|
-
- HY-14810
-
|
AVE-2268
|
SGLT
|
Metabolic Disease
|
|
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .
|
-
- HY-117446
-
|
|
GPR119
|
Metabolic Disease
|
|
AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .
|
-
- HY-11051
-
|
|
Opioid Receptor
|
Inflammation/Immunology
|
|
JNJ-20788560 is a selective and orally active delta opioid receptor agonist with an affinity of 2.0 nM for DOR (rat brain cortex binding assay). JNJ-20788560 also is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. JNJ-20788560 can be used for the research of the relief of inflammatory hyperalgesia .
|
-
- HY-163507
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
ALK5-IN-79 (compound 57) is an ALK inhibitor with anticancer activity, by blocking TGF-β1/SMAD signaling pathway. ALK5-IN-79 attenuates the production of extracellular matrix (ECM) and deposition of collagen. ALK5-IN-79 exhibits adequate pharmacokinetic (PK) properties and good in vivo tolerance.
|
-
- HY-113478R
-
|
Isoursodeoxycholic acid (Standard)
|
Drug Metabolite
Reference Standards
|
Metabolic Disease
|
|
3β-Ursodeoxycholic acid (Standard) is the analytical standard of 3β-Ursodeoxycholic acid. This product is intended for research and analytical applications. 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .
|
-
- HY-161892
-
|
|
FABP
|
Metabolic Disease
Inflammation/Immunology
|
|
FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .
|
-
- HY-B1282AR
-
|
|
Reference Standards
Bacterial
Parasite
Antibiotic
|
Infection
|
|
3β-Ursodeoxycholic acid (Standard) is the analytical standard of 3β-Ursodeoxycholic acid. This product is intended for research and analytical applications. 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .
|
-
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
-
- HY-131334
-
|
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
|
-
- HY-B0853R
-
|
|
Reference Standards
Fungal
|
Infection
|
|
Paclobutrazol (Standard) is the analytical standard of Paclobutrazol. This product is intended for research and analytical applications. Paclobutrazol is a triazole-containing plant growth retardant that is known to inhibit the biosynthesis of gibberellins. Paclobutrazol also has antifungal activities. Paclobutrazol, transported acropetally in plants, can also suppress the synthesis of abscisic acid and induce chilling tolerance in plants. Paclobutrazol is typically used to support research on the role of gibberellins in plant biology .
|
-
- HY-106840
-
|
|
Cholecystokinin Receptor
|
Neurological Disease
Metabolic Disease
|
|
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .
|
-
- HY-117446A
-
|
|
GPR119
|
Metabolic Disease
|
|
AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.
|
-
- HY-116003
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders .
|
-
- HY-160602
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
|
-
- HY-162423
-
|
|
5-HT Receptor
Androgen Receptor
|
Neurological Disease
|
|
CYB210010 is an orally bioavailable, long-acting serotonin 5-HT2 receptor agonist that selectively targets 5-HT2A and 5-HT2C receptors (EC50: 4.1 n, 7.3 nM). CYB210010 can enter the central nervous system, cause a head twitch response (HTR), and is not prone to behavioral tolerance during chronic administration .
|
-
- HY-13991A
-
|
|
Ras
|
Metabolic Disease
Cancer
|
|
(S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes .
|
-
- HY-133180
-
|
|
Wnt
β-catenin
|
Metabolic Disease
|
|
YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .
|
-
- HY-100604
-
|
|
γ-secretase
Amyloid-β
|
Neurological Disease
|
|
JNJ-40418677 is an orally active modulator of γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42 and NS2B-NS3 protease, with IC50s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research .
|
-
- HY-13991R
-
|
|
Ras
Apoptosis
|
Cancer
|
|
CCG-1423 (Standard) is the analytical standard of CCG-1423. This product is intended for research and analytical applications. CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
|
-
- HY-13991
-
|
|
Ras
Apoptosis
|
Cancer
|
|
CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
|
-
- HY-117459
-
|
|
PPAR
|
Metabolic Disease
|
|
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
|
-
- HY-155967
-
|
|
AMPK
Cannabinoid Receptor
|
Metabolic Disease
|
|
CB1R/AMPK modulator 1 (Compound 38-S) is an orally active CB1R/AMPK modulator, with an Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. CB1R/AMPK modulator 1 activates AMPK. CB1R/AMPK modulator 1 reduces food intake and body weight, and improves glucose tolerance and insulin sensitivity .
|
-
- HY-133677
-
|
MEHHP
|
Drug Metabolite
|
Endocrinology
|
|
Mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) is an oxidative metabolite of Di(2-ethylhexyl) phthalate (DEHP). Mono(2-ethyl-5-hydroxyhexyl) phthalate may protective sperm DNA damage. Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
- HY-173130
-
|
|
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC50 of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .
|
-
- HY-173016
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
HINT1-IN-1 (Compound 8) is the inhibitor for histidine triad nucleotide-binding protein 1 (HINT1) with a Ki of 1.14 μM. HINT1-IN-1 affects the cross-regulation between μ-opioid receptor (MOR) and NMDA receptor (NMDAR). HINT1-IN-1 enhances the analgesic effect of morphine without causing opioid tolerance and has independent analgesic effects in mouse model .
|
-
- HY-N15721
-
|
Trp-CA
|
Orphan GPCR
|
Metabolic Disease
|
|
Tryptophan-cholic acid (Trp-CA) is a microbial amino-acid-conjugated bile acid, serving as an endogenous ligand and agonist of the orphan G protein-coupled receptor (GPCR) MRGPRE. Tryptophan-cholic acid activates MRGPRE, promoting the secretion of glucagon-like peptide-1 (GLP-1) through the Gs-cAMP and β-arrestin-1-ALDOA signaling pathways, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid is promising for research of type 2 diabetes .
|
-
- HY-172874
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
|
-
- HY-P99584
-
|
KD-247
|
HIV
|
Infection
|
|
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
|
-
- HY-159923
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation .
|
-
- HY-146725
-
|
|
FBPase
|
Metabolic Disease
|
|
FBPase-IN-1 is a potent FBPase (Fructose-1,6-bisphosphatase) inhibitor for Type 2 diabetes (T2D) study with an IC50 of 0.22 μM. FBPase-IN-1 can reduce blood glucose levels and ameliorate glucose tolerance. FBPase-IN-1 modifies the C128 site, regulates the N125-S124-S123 allosteric pathway of FBPase and affects the catalytic activity of FBPase .
|
-
- HY-164519
-
|
|
Apoptosis
Mps1
Mitosis
|
Cancer
|
|
PF-7006 is an Mps1 kinase inhibitor with a Ki value of 0.27 nM and an IC50 value of 2.5 nM. PF-7006 interferes with cell cycle checkpoints by inhibiting the catalytic activity of Mps1, reducing histone H3 levels, and shortening the duration of mitosis, leading to apoptosis in cancer cells. Combined use of PF-7006 with Palbociclib (HY-50767) increases cancer cell tolerance to PF-7006. PF-7006 can be used for breast cancer research .
|
-
- HY-P10394
-
-
- HY-111011
-
|
JNJ 38488502 acetate; FE 200665 acetate
|
Opioid Receptor
|
Neurological Disease
|
|
CR 665 (JNJ 38488502) acetate is a kappa-opioid agonist that may effectively treat visceral pain by activating receptors on afferent nerves within the gut. CR 665 acetate exhibits peripheral selectivity, differentiating its pharmacokinetic profile from that of non-selective opioids like oxycodone. CR 665 acetate has demonstrated a beneficial effect on visceral pain tolerance thresholds without the delayed analgesic response characteristic of opioids that penetrate the brain. CR 665 acetate is proposed for use in managing postoperative pain due to its pain-relieving properties.
|
-
- HY-B1329
-
|
Nebramycin II sulfate
|
Bacterial
Antibiotic
|
Infection
|
|
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .
|
-
- HY-B1329R
-
|
Nebramycin II sulfate (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
|
-
- HY-P3247
-
|
|
Insulin Receptor
|
Neurological Disease
Metabolic Disease
|
|
[D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
|
-
![[D-Ala2]-GIP (human)](//file.medchemexpress.eu/product_pic/hy-p3247.gif)
- HY-147678
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-P0165B
-
|
ITM077 acetate; R1583 acetate; BIM51077 acetate
|
GLP Receptor
|
Metabolic Disease
|
|
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
|
-
- HY-161823
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 13 (Compound 9b) is an agent against methicillin-resistant Staphylococcus aureus (MRSA), exhibiting a minimum inhibitory concentration (MIC) of 0.5–2 μg/mL against clinically isolated MRSA strains. Anti-MRSA agent 13 possesses favorable biosafety, plasma tolerance stability, and a low tendency to develop resistance. Anti-MRSA agent 13 disrupts cell walls and membranes, reduces metabolic activity, causes oxidative damage, affects DNA function, and ultimately leads to MRSA death through multi-target synergies .
|
-
- HY-139792
-
|
SHR117887
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
|
-
- HY-P99667
-
|
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
-
- HY-121744
-
PS10
3 Publications Verification
|
PDHK
|
Inflammation/Immunology
|
|
PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC50 of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (Kd= 239 nM) than for Hsp90 (Kd= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase
|
-
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
-
- HY-W709755
-
|
MECPP-d9
|
Isotope-Labeled Compounds
Drug Metabolite
|
Others
|
|
Mono(5-carboxy-2-ethylpentyl) phthalate-d9 (MECPP-d9) is the deuterium labeled Mono(5-carboxy-2-ethylpentyl) phthalate (HY-133675). Mono(5-carboxy-2-ethylpentyl) phthalate (MECPP) is a metabolite of Di-(2-ethylhexyl) phthalate (DEHP). Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
- HY-133675S
-
|
MECPP-d4
|
Isotope-Labeled Compounds
Drug Metabolite
|
Others
|
|
Mono(5-carboxy-2-ethylpentyl) phthalate-d4 (MECPP-d4) is a deuterium labeled Mono(5-carboxy-2-ethylpentyl) phthalate (HY-133675). Mono(5-carboxy-2-ethylpentyl) phthalate (MECPP) is a metabolite of Di-(2-ethylhexyl) phthalate (DEHP). Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
- HY-N8518
-
|
|
Phospholipase
p38 MAPK
Apoptosis
NF-κB
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .
|
-
- HY-12191
-
|
|
Histamine Receptor
|
Metabolic Disease
|
|
A-331440 is a potent and selective histamine H3 receptor antagonist that regulates neurotransmitter release by inhibiting presynaptic H3 receptors. In preclinical studies involving mice on a high-fat diet, A-331440 demonstrated dose-dependent effects on weight reduction and fat loss. At 5 mg/kg, it effectively decreased body weight comparable to dexfenfluramine, while at 15 mg/kg, it significantly reduced body fat and improved insulin tolerance, similar to mice on a low-fat diet. These findings suggest that A-331440 holds promise as an antiobesity agent by modulating histaminergic pathways involved in food intake and metabolic regulation .
|
-
- HY-12443
-
|
|
Casein Kinase
|
Neurological Disease
|
|
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .
|
-
- HY-125327
-
|
|
SGLT
|
Metabolic Disease
|
|
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.
|
-
- HY-W012382
-
|
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate FoxO and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .
|
-
- HY-133676S
-
|
|
Isotope-Labeled Compounds
Drug Metabolite
|
Others
|
|
Mono(2-ethyl-5-oxohexyl) phthalate-d4 is a deuterium labeled Mono(2-ethyl-5-oxohexyl) phthalate (HY-133676). Mono(2-ethyl-5-oxohexyl) phthalate is an oxidative metabolite of Di(2-ethylhexyl) phthalate (DEHP). Mono(2-ethyl-5-oxohexyl) phthalate may protective sperm DNA damage. Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
- HY-117881
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
CJ-15208 is a potent and selective κ-opioid receptor antagonist with significant opioid activity. CJ-15208 exhibited strong analgesic effects in the warm water tail withdrawal test in mice and was mediated through multiple opioid receptors. The stereoisomers of CJ-15208 exhibited different opioid activity characteristics, for example, one stereoisomer exhibited κ-opioid receptor antagonism, while the other exhibited δ-opioid receptor antagonism. All stereoisomers of CJ-15208 had no significant effects on respiration. The stereoisomers of CJ-15208 did not lead to the development of drug tolerance, which makes it potential in the further development of safe opioid analgesics .
|
-
- HY-155156
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .
|
-
- HY-120828
-
|
CJC 1134PC
|
GLP Receptor
|
Metabolic Disease
|
|
Albenatide (CJC 1134PC) is a modified Exendin-4 (HY-13443) analogue conjugated to human recombinant albumin (HRA) in vitro to form a long-acting DPP-4-resistant GLP-1R agonist. Albenatide covalently binds through a low-molecular chemical linker (cys-C13H19O6N3-lys) to the cysteine residue in position 34 of HRA. Albenatide increases cyclic AMP (cAMP) production in vitro. Albenatide reduces glucose excursions, food intake, gastric emptying in wild-type mice and improves glucose tolerance and reduces body weight in high-fat diet mice .
|
-
- HY-155157
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .
|
-
- HY-133677S
-
|
MEHHP-d4
|
Isotope-Labeled Compounds
Drug Metabolite
|
Others
|
|
Mono(2-ethyl-5-hydroxyhexyl) phthalate-d4 (MEHHP-d4) is a deuterium labeled Mono(2-ethyl-5-hydroxyhexyl) phthalate (HY-133677). Mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) is an oxidative metabolite of Di(2-ethylhexyl) phthalate (DEHP). Mono(2-ethyl-5-hydroxyhexyl) phthalate may protective sperm DNA damage. Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
- HY-173479
-
|
|
GLP Receptor
|
Cardiovascular Disease
Metabolic Disease
|
|
GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC50 of 0.048 nM. GLP-1R has excellent selectivity, with EC50 greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice .
|
-
- HY-W012382R
-
|
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
N-Acetyl-L-tyrosine (Standard) is the analytical standard of N-Acetyl-L-tyrosine (HY-W012382). This product is intended for research and analytical applications. N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate FoxO and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .
|
-
- HY-W012382S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
N-Acetyl-L-tyrosine-d3 is the deuterated form of N-Acetyl-L-tyrosine (HY-W012382). N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate FoxO and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .
|
-
- HY-126855
-
|
7-Sulfocholic acid
|
G protein-coupled Bile Acid Receptor 1
MHC
|
Metabolic Disease
|
|
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
- HY-126855S
-
|
7-Sulfocholic acid-d4
|
Isotope-Labeled Compounds
G protein-coupled Bile Acid Receptor 1
MHC
|
Metabolic Disease
|
|
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
| Cat. No. |
Product Name |
Type |
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0046
-
|
GHK; Tripeptide-1
|
Peptides
|
Neurological Disease
Inflammation/Immunology
|
|
Glycyl-L-histidyl-L-lysine is a tripeptide consisting of glycine, L-histidine and L-lysine residues joined in sequence. Glycyl-L-histidyl-L-lysine is a hepatotropic immunosuppressor and shows anxiolytic effect. Glycyl-L-histidyl-L-lysine and its copper complexes show good skin tolerance .
|
-
- HY-P1290A
-
|
PKI-(6-22)-amide TFA
|
PKA
|
Neurological Disease
|
|
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
|
-
- HY-P1291
-
|
|
PKA
Epigenetic Reader Domain
Flavivirus
|
Infection
Neurological Disease
|
|
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
|
-
- HY-P1291A
-
|
|
PKA
Epigenetic Reader Domain
Flavivirus
|
Infection
Neurological Disease
|
|
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
|
-
- HY-P1434
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .
|
-
- HY-P3247
-
|
|
Insulin Receptor
|
Neurological Disease
Metabolic Disease
|
|
[D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
|
-
- HY-P2194
-
|
|
Peptides
|
Inflammation/Immunology
|
|
AtPep3 is a hormone-like peptide. AtPep3 can enhance salinity tolerance of plants and inhibits the salt-induced bleaching of chlorophyll in seedlings .
|
-
- HY-P2194A
-
|
|
Peptides
|
Inflammation/Immunology
|
|
AtPep3 TFA is a hormone-like peptide. AtPep3 TFA can enhance salinity tolerance of plants and inhibits the salt-induced bleaching of chlorophyll in seedlings .
|
-
- HY-P1290
-
|
PKI-(6-22)-amide
|
PKA
|
Neurological Disease
|
|
PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .
|
-
- HY-P10394
-
-
- HY-P0165B
-
|
ITM077 acetate; R1583 acetate; BIM51077 acetate
|
GLP Receptor
|
Metabolic Disease
|
|
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
|
-
- HY-K1041
-
2 Publications Verification
|
|
MCE Seamless DNA Assembly Plus Kit contains an optimized mix of recombinase, reaction buffer, and additional cofactors that significantly improve the cloning efficiency and tolerance to impurities. This product can complete multiple DNA fragments recombination and takes only 5 minutes for single fragment, and the positive rate is more than 95%.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
-
- HY-P99584
-
|
KD-247
|
HIV
|
Infection
|
|
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
|
-
- HY-P99667
-
|
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
-
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-150012S1
-
|
|
|
N-Lactoyl-Phenylalanine- 13C6 (Lac-Phe- 13C6) is 13C labeled N-Lactoyl-Phenylalanine. N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .
|
-
-
- HY-133675S
-
|
|
|
Mono(5-carboxy-2-ethylpentyl) phthalate-d4 (MECPP-d4) is a deuterium labeled Mono(5-carboxy-2-ethylpentyl) phthalate (HY-133675). Mono(5-carboxy-2-ethylpentyl) phthalate (MECPP) is a metabolite of Di-(2-ethylhexyl) phthalate (DEHP). Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
-
- HY-133676S
-
|
|
|
Mono(2-ethyl-5-oxohexyl) phthalate-d4 is a deuterium labeled Mono(2-ethyl-5-oxohexyl) phthalate (HY-133676). Mono(2-ethyl-5-oxohexyl) phthalate is an oxidative metabolite of Di(2-ethylhexyl) phthalate (DEHP). Mono(2-ethyl-5-oxohexyl) phthalate may protective sperm DNA damage. Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
-
- HY-133677S
-
|
|
|
Mono(2-ethyl-5-hydroxyhexyl) phthalate-d4 (MEHHP-d4) is a deuterium labeled Mono(2-ethyl-5-hydroxyhexyl) phthalate (HY-133677). Mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) is an oxidative metabolite of Di(2-ethylhexyl) phthalate (DEHP). Mono(2-ethyl-5-hydroxyhexyl) phthalate may protective sperm DNA damage. Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
-
- HY-W012382S
-
|
|
|
N-Acetyl-L-tyrosine-d3 is the deuterated form of N-Acetyl-L-tyrosine (HY-W012382). N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate FoxO and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer .
|
-
-
- HY-139289S
-
|
|
|
ART899 is a highly specific allosteric inhibitor of the Polθ DNA polymerase domain. ART899 can effectively enhance the radiosensitivity of tumor cells, shows good tolerance when combined with fractionated radiation, and significantly reduces tumor growth compared to radiation alone .
|
-
-
- HY-W709755
-
|
|
|
Mono(5-carboxy-2-ethylpentyl) phthalate-d9 (MECPP-d9) is the deuterium labeled Mono(5-carboxy-2-ethylpentyl) phthalate (HY-133675). Mono(5-carboxy-2-ethylpentyl) phthalate (MECPP) is a metabolite of Di-(2-ethylhexyl) phthalate (DEHP). Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking .
|
-
-
- HY-126855S
-
|
|
|
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[Pro3]-GIP (mouse)](http://file.medchemexpress.eu/product_pic/hy-p1434.gif)
![[D-Ala2]-GIP (human)](http://file.medchemexpress.eu/product_pic/hy-p3247.gif)
